Subacute sclerosing panencephalitis: Oral: 50 mg/kg/day in 3 to 4 equally divided doses (maximum: 3 g daily).
There is no dosage adjustment provided in manufacturer’s labeling.
There is no dosage adjustment provided in manufacturer’s labeling.
Refer to adult dosing.
Subacute sclerosing panencephalitis (SSPE): Refer to adult dosing.
There is no dosage adjustment provided in manufacturer’s labeling.
There is no dosage adjustment provided in manufacturer’s labeling.
The following adverse drug reactions are derived from product labeling unless otherwise specified.
Frequency not defined:
Dermatologic: Pruritus, skin rash
Endocrine & metabolic: Hyperuricemia
Gastrointestinal: Constipation, diarrhea, gastric distress
Genitourinary: Hyperuricuria, increased urine output
Nervous system: Dizziness, fatigue, headache, insomnia, nervousness
Neuromuscular & skeletal: Arthralgia
There are no contraindications listed in the manufacturer’s product monograph.
Concerns related to adverse effects:
• Uric acid: Inosine undergoes rapid metabolism to uric acid. Use with caution in patients with a history of gout, urolithiasis, nephrolithiasis, or kidney impairment. Uricosuric agents (eg, probenecid) or antihyperuricemic therapy (eg, allopurinol) may be necessary for extremely elevated serum uric acid levels.
Not available in the US
No
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet, Oral:
Imunovir: 500 mg
Oral: Administer orally in 3 to 4 equally divided doses while awake.
Oral: Administer orally in 3 to 4 equally divided doses while awake.
Note: Not approved in the US.
Treatment of slowly progressive subacute sclerosing panencephalitis; may delay neurologic deterioration and prolong life expectancy.
None known.
There are no known significant interactions.
Adverse effects to the fetus were not observed in animal reproduction studies. Due to the altered immune status of patients who are pregnant, subacute sclerosing panencephalitis may be exacerbated during pregnancy and may progress rapidly. Because this condition is rare, use of inosine pranobex in pregnancy is limited to case reports (Cole 2007).
Uric acid (serum and urine)
Exact mechanism has not been fully elucidated; may possess antiviral and immunomodulating effects by potentiating T-lymphocyte and macrophage cell function and by influencing cytokine production (Milano, 1991; Petrova, 2010; Wybran, 1978).
Metabolism: Rapid to uric acid; also undergoes glucuronidation and oxidation
Half-life elimination: ~50 minutes (Campoli-Richards, 1986)
Time to peak: 1 hour (Campoli-Richards, 1986)
Excretion: Urine (as uric acid, glucuronide and oxide metabolites, and unchanged drug)
Do you want to add Medilib to your home screen?